Developer docs
API playgroundTry for free, no card

Search company profiles

KSQ Therapeutics

Full company profile

uuid00045ez

Namestring
KSQ Therapeutics
Legal namestring
KSQ Therapeutics, Inc.
Websiteurl
ksqtx.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

KSQ Therapeutics is a clinical-stage biotechnology company founded in 2015 and headquartered in Lexington, Massachusetts, that applies its proprietary CRISPRomics® genome-scale functional genomics platform to identify and validate therapeutic targets in oncology and immunology. The platform conducts unbiased, in vivo CRISPR screening across more than 20,000 human genes and 600+ cancer and immune cell models, and has been used to nominate first-in-class targets including SOCS1, Regnase-1, and USP1. KSQ's lead pipeline consists of CRISPR/Cas9-engineered Tumor Infiltrating Lymphocyte (eTIL®) therapies — KSQ-001EX (single SOCS1 knockout) and KSQ-004EX (dual SOCS1/Regnase-1 knockout) — both manufactured through the proprietary 22-day ExPRESS™ process and currently in Phase 1/2 trials across multiple solid tumor indications including melanoma, head and neck squamous cell carcinoma, non-small cell lung cancer, colorectal cancer, pancreatic cancer, and cervical cancer. KSQ-4279, a first-in-class USP1 small-molecule inhibitor, has been out-licensed worldwide to Roche, and multiple research-stage DDR programs have been acquired by Ono Pharmaceutical.

The business model is a partnership-driven biotech model rather than a commercial product model. KSQ generates revenue from upfront payments, development and commercialization milestones, and royalties on partnered programs — with disclosed potential milestone exposure of more than $1 billion across the Takeda collaborations (2021 and 2023 expansion), Roche agreement (2023), and Ono transaction (2023). Equity capital raised totals approximately $156 million ($76M founding financing in October 2017 and $80M Series C in September 2018) from Flagship Pioneering, Polaris Partners, ARCH Venture Partners, Alexandria Equities, Baillie Gifford, Cowen Healthcare Investments, Invus, and Lilly Asia Ventures. The company has built an operational ecosystem comprising a clinical collaboration with MD Anderson Cancer Center for the eTIL trials, a manufacturing partnership with CTMC (a National Resilience/MD Anderson joint venture), a non-exclusive cross-license with CRISPR Therapeutics for editing IP, and a cell engineering platform agreement with MaxCyte.

Short descriptiontext

KSQ Therapeutics is a clinical-stage biotechnology company using its proprietary CRISPRomics® functional genomics platform to discover and develop CRISPR/Cas9-engineered Tumor Infiltrating Lymphocyte (eTIL®) therapies and targeted oncology drugs for advanced solid tumors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLexington, United States
HQ citystring
Lexington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
functional genomics, cell therapy oncology, CRISPR drug discovery, tumor infiltrating lymphocytes, engineered cell therapies
Industry2 codes
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Oncology Biotechnology / Cell Therapy
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Upfront payments, development and commercialization milestone payments, and royalties on net sales from strategic partnerships. Takeda deal: potential for more than $100M upfront and preclinical milestones, up to $400M+ per program in additional milestones plus royalties. Takeda expansion: upfront and investment in double-digit millions, up to $510M in future payments plus royalties. Roche: upfront and additional milestone and royalty payments.

ksqtx.com
2Equity Financing
TypeLicensing Royalties
Description

Series financing rounds. $76M financing at founding in October 2017. $80M Series C financing in September 2018. Investors include Flagship Pioneering, Polaris Partners, ARCH Venture Partners, Baillie Gifford, Cowen Healthcare Investments, Invus, Lilly Asia Ventures.

ksqtx.com
3Program Acquisitions
TypeLicensing Royalties
Description

ONO Pharmaceutical acquired multiple research-stage DDR programs with double-digit million upfront payment, near-term milestones, potential long-term value into triple-digit millions plus royalties on net sales

ksqtx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

KSQ Therapeutics is a clinical-stage biotechnology company that discovers and develops oncology therapeutics using its proprietary CRISPRomics® genome-scale functional genomics platform. The company is advancing a pipeline of CRISPR/Cas9-engineered Tumor Infiltrating Lymphocyte (eTIL®) therapies, including KSQ-001EX and KSQ-004EX, manufactured via its proprietary ExPRESS™ process, and has out-licensed the small-molecule USP1 inhibitor KSQ-4279 to Roche.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 10-fold increase in anti-tumor activity in vivo with CT-1 edited T cells
+2 more records
Product overview1 text field

KSQ Therapeutics is a clinical-stage biotechnology company developing a portfolio of cancer therapies powered by its proprietary CRISPRomics® functional genomics platform. The company's core offerings include two CRISPR/Cas9-engineered Tumor Infiltrating Lymphocyte (eTIL®) therapies—KSQ-001EX (single SOCS1 gene inactivation) and KSQ-004EX (dual SOCS1/Regnase-1 inactivation)—both manufactured using the company's proprietary ExPRESS™ process. Additionally, KSQ-4279, a first-in-class USP1 small-molecule inhibitor for DNA damage response, was out-licensed to Roche. The CRISPRomics platform enables genome-scale, in vivo validated target discovery, while the ExPRESS process enables efficient manufacturing of edited cell therapies from both surgical resections and core biopsies.

Product and service5 records
1CRISPRomics® Platform
CategoryPlatform / Drug Discovery Engine
Description

Proprietary genome-scale functional genomics platform using CRISPR/Cas9 technology to systematically identify and validate therapeutic targets across cancer and immune cells. Screens over 20,000 genes across more than 600 cancer lines and immune cell types (T cells, NK cells, T regulatory cells) for unbiased, in vivo validated target discovery.

2ExPRESS™ Manufacturing Process
CategoryCell Therapy Manufacturing Process
Description

Proprietary next-generation manufacturing process (Ex Vivo, Potent, Economical, Streamlined, Simple) for producing single and multiplex CRISPR/Cas9-edited eTIL therapies. Generates a cryopreserved product with maximized cancer-killing potential from surgical resections and core biopsies using a 22-day manufacturing cycle across 10+ solid tumor types.

3KSQ-001EX
CategoryEngineered Cell Therapy (eTIL)
Description

Investigational CRISPR/Cas9-engineered Tumor Infiltrating Lymphocyte (eTIL®) therapy in which the SOCS1 gene is inactivated, manufactured using the ExPRESS™ process. In Phase 1/2 clinical study for advanced solid tumors including melanoma, head and neck squamous cell carcinoma, and non-small cell lung cancer.

4KSQ-004EX
CategoryEngineered Cell Therapy (eTIL)
Description

Dual-edit eTIL investigational therapy in which both the Regnase-1 and SOCS1 genes are inactivated by CRISPR/Cas9 gene editing, manufactured using the ExPRESS™ process. In Phase 1/2 clinical study for advanced solid tumors including melanoma, head and neck squamous cell carcinoma, non-small cell lung cancer, colorectal cancer, pancreatic cancer, and cervical cancer.

5KSQ-4279 (RO7623066/RG6614)
CategorySmall-Molecule Targeted Oncology (Licensed)
Description

First-in-class, potent, and selective small-molecule inhibitor of USP1 (Ubiquitin-specific processing protease 1), a protein regulating DNA damage response (DDR). Licensed worldwide to Roche for development and commercialization; previously studied in Phase 1 clinical trial in patients with advanced solid tumors including BRCA-mutant and HRD cancers.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2024-09-24
Description

Clinical collaboration for KSQ-004EX Phase 1/2 study. MD Anderson provides clinical trial site and principal investigator Dr. Rodabe Amaria (professor of Melanoma Medical Oncology). Also collaborates on KSQ-001EX study.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-06
Description

Strategic collaboration with CTMC, a joint venture between National Resilience, Inc. and MD Anderson Cancer Center. CTMC provides full process development and manufacturing support for KSQ's lead eTIL programs KSQ-001EX and KSQ-004EX, advancing toward clinical studies for solid tumors. Manufacturing uses KSQ's ExPRESS process.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-07-13
Description

Worldwide license and collaboration agreement for KSQ-4279, a first-in-class USP1 inhibitor for cancer. Roche assumes development responsibilities including full clinical development from 2024. KSQ receives upfront payment and eligible for milestone and royalty payments. KSQ-4279 is in Phase 1 clinical trial for advanced solid tumors.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-17
Description

Expanded collaboration focused on novel tumor-intrinsic target discovery and validation. Takeda provides upfront payment and investment in double-digit millions. KSQ eligible for up to $510M in future payments if all milestones achieved, plus royalties on net sales. Expansion adds work on tumor-intrinsic targets to ongoing NK and T-cell collaboration.

5Ono Pharmaceutical Co., Ltd.
Strategic tierKeyTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-01-25
Description

Ono Pharmaceutical acquired multiple research-stage DNA damage response (DDR) programs identified using KSQ's CRISPRomics platform. All programs are novel with potential for first-in-class therapies. ONO provided double-digit million upfront payment with near-term milestones expected and potential long-term value into triple-digit millions plus royalties on net sales.

ksqtx.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-13
Description

Broad strategic collaboration to research, develop and commercialize novel immune-based therapies for cancer. KSQ granted Takeda exclusive worldwide royalty-bearing license for cell and non-cell therapy products modulating targets identified using CRISPRomics. Deal includes two T-cell programs and NK cell target discovery. Potential for $100M+ upfront and preclinical milestones, up to $400M+ per program additional milestones plus royalties. KSQ retains U.S. cost/profit-sharing option on one product.

Strategic tierKeyTypeTechnology or IntegrationAnnounced on2019-12-04
Description

Development and commercialization agreement using MaxCyte's Flow Electroporation technology and ExPERT instruments for KSQ's eTIL programs. KSQ obtains non-exclusive clinical and commercial use rights to MaxCyte's cell engineering platform for multiple adoptive cell therapies. MaxCyte eligible for milestone payments and licensing fees.

Strategic tierKeyTypeTechnology or IntegrationAnnounced on2019-10-15
Description

License agreement for mutual IP access. CRISPR Therapeutics gains non-exclusive access to KSQ IP for editing certain novel gene targets in its allogeneic oncology cell therapy programs. KSQ gains non-exclusive access to CRISPR Therapeutics IP for editing novel gene targets in its autologous eTIL cell programs.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Beam is a clinical-stage precision genetic medicines company using base editing, a CRISPR-derived technology. Comparable platform-driven biotech with similar oncology focus and partnership approach (Pfizer, Verve).

TypeDirect peer
Description

Intellia is a clinical-stage CRISPR/Cas9 platform company developing both ex vivo (cell therapy) and in vivo gene editing programs. Similar platform-technology profile and partnership-driven business model with comparable Big Pharma validation (Novartis, Regeneron).

TypeEmerging player
Description

Cellectis develops TALEN-based gene-edited allogeneic CAR-T cell therapies. Comparable gene-edited cell therapy approach but earlier stage in clinical development and focused on allogeneic platform.

TypeEmerging player
Description

Allogene is a clinical-stage allogeneic CAR-T company with multiple programs in lymphoma and other hematologic malignancies. Comparable cell therapy platform approach and Big Pharma backing (Pfizer, Cellectis founder).

TypeDirect peer
Description

Iovance is the most direct peer - the leader in TIL therapy with FDA-approved lifileucel for melanoma. KSQ's eTIL programs compete head-to-head in melanoma and other solid tumors, and Iovance's commercial experience directly benchmarks KSQ's opportunity and challenges.

TypeDirect peer
Description

Adaptimmune develops engineered T-cell receptor (TCR) therapies for solid tumors, with approved Tecelra for synovial sarcoma. Direct competitor in the solid tumor cell therapy space where KSQ's eTIL programs also operate.

TypeEmerging player
Description

Caribou is a clinical-stage CRISPR genome-edited allogeneic CAR-T and NK cell therapy company. Comparable gene-edited cell therapy technology profile but with allogeneic (off-the-shelf) rather than KSQ's autologous approach.

TypeDirect peer
Description

Editas is a clinical-stage CRISPR gene editing company developing edited cell therapies for oncology and genetic diseases. Comparable platform-technology approach and similar partnership-driven development model.

TypeDirect peer
Description

CRISPR Therapeutics is the most direct CRISPR platform peer, with its Cas9-based allogeneic CAR-T programs. KSQ has a mutual license with CRISPR Therapeutics (2019) and competes for the same gene-edited cell therapy opportunity, with overlapping target space.

TypeEmerging player
Description

Fate develops iPSC-derived off-the-shelf NK and T-cell cancer immunotherapies. Comparable cell therapy modality for oncology with multiple Big Pharma partnerships (J&J, Ono), analogous to KSQ's licensing model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

KSQ Therapeutics

Oncology Biotechnology / Cell Therapyksqtx.com

KSQ Therapeutics is a clinical-stage biotechnology company using its proprietary CRISPRomics® functional genomics platform to discover and develop CRISPR/Cas9-engineered Tumor Infiltrating Lymphocyte (eTIL®) therapies and targeted oncology drugs for advanced solid tumors.

What KSQ Therapeutics does

KSQ Therapeutics is a clinical-stage biotechnology company founded in 2015 and headquartered in Lexington, Massachusetts, that applies its proprietary CRISPRomics® genome-scale functional genomics platform to identify and validate therapeutic targets in oncology and immunology. The platform conducts unbiased, in vivo CRISPR screening across more than 20,000 human genes and 600+ cancer and immune cell models, and has been used to nominate first-in-class targets including SOCS1, Regnase-1, and USP1. KSQ's lead pipeline consists of CRISPR/Cas9-engineered Tumor Infiltrating Lymphocyte (eTIL®) therapies — KSQ-001EX (single SOCS1 knockout) and KSQ-004EX (dual SOCS1/Regnase-1 knockout) — both manufactured through the proprietary 22-day ExPRESS™ process and currently in Phase 1/2 trials across multiple solid tumor indications including melanoma, head and neck squamous cell carcinoma, non-small cell lung cancer, colorectal cancer, pancreatic cancer, and cervical cancer. KSQ-4279, a first-in-class USP1 small-molecule inhibitor, has been out-licensed worldwide to Roche, and multiple research-stage DDR programs have been acquired by Ono Pharmaceutical.

The business model is a partnership-driven biotech model rather than a commercial product model. KSQ generates revenue from upfront payments, development and commercialization milestones, and royalties on partnered programs — with disclosed potential milestone exposure of more than $1 billion across the Takeda collaborations (2021 and 2023 expansion), Roche agreement (2023), and Ono transaction (2023). Equity capital raised totals approximately $156 million ($76M founding financing in October 2017 and $80M Series C in September 2018) from Flagship Pioneering, Polaris Partners, ARCH Venture Partners, Alexandria Equities, Baillie Gifford, Cowen Healthcare Investments, Invus, and Lilly Asia Ventures. The company has built an operational ecosystem comprising a clinical collaboration with MD Anderson Cancer Center for the eTIL trials, a manufacturing partnership with CTMC (a National Resilience/MD Anderson joint venture), a non-exclusive cross-license with CRISPR Therapeutics for editing IP, and a cell engineering platform agreement with MaxCyte.

KSQ Therapeutics firmographics

Firmographics
Name
KSQ Therapeutics
Legal name
KSQ Therapeutics, Inc.
Website
https://ksqtx.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
KSQ Therapeutics is a clinical-stage biotechnology company using its proprietary CRISPRomics® functional genomics platform to discover and develop CRISPR/Cas9-engineered Tumor Infiltrating Lymphocyte (eTIL®) therapies and targeted oncology drugs for advanced solid tumors.
Ownership category
akta.pro rank

KSQ Therapeutics industry classification

Industry
Product category
Oncology Biotechnology / Cell Therapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Functional genomics
  • Cell therapy oncology
  • CRISPR drug discovery
  • Tumor infiltrating lymphocytes
  • Engineered cell therapies

Where KSQ Therapeutics is headquartered

Location

Headquarters

HQ city
Lexington
HQ country
United States
HQ region
North America

Offices2 records

Markets served

KSQ Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

  1. Licensing and Milestone Payments: Upfront payments, development and commercialization milestone payments, and royalties on net sales from strategic partnerships. Takeda deal: potential for more than $100M upfront and preclinical milestones, up to $400M+ per program in additional milestones plus royalties. Takeda expansion: upfront and investment in double-digit millions, up to $510M in future payments plus royalties. Roche: upfront and additional milestone and royalty payments.
  2. Equity Financing: Series financing rounds. $76M financing at founding in October 2017. $80M Series C financing in September 2018. Investors include Flagship Pioneering, Polaris Partners, ARCH Venture Partners, Baillie Gifford, Cowen Healthcare Investments, Invus, Lilly Asia Ventures.
  3. Program Acquisitions: ONO Pharmaceutical acquired multiple research-stage DDR programs with double-digit million upfront payment, near-term milestones, potential long-term value into triple-digit millions plus royalties on net sales

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

KSQ Therapeutics product offering

Product offering

Core offering

KSQ Therapeutics is a clinical-stage biotechnology company that discovers and develops oncology therapeutics using its proprietary CRISPRomics® genome-scale functional genomics platform. The company is advancing a pipeline of CRISPR/Cas9-engineered Tumor Infiltrating Lymphocyte (eTIL®) therapies, including KSQ-001EX and KSQ-004EX, manufactured via its proprietary ExPRESS™ process, and has out-licensed the small-molecule USP1 inhibitor KSQ-4279 to Roche.

Product overview

KSQ Therapeutics is a clinical-stage biotechnology company developing a portfolio of cancer therapies powered by its proprietary CRISPRomics® functional genomics platform. The company's core offerings include two CRISPR/Cas9-engineered Tumor Infiltrating Lymphocyte (eTIL®) therapies—KSQ-001EX (single SOCS1 gene inactivation) and KSQ-004EX (dual SOCS1/Regnase-1 inactivation)—both manufactured using the company's proprietary ExPRESS™ process. Additionally, KSQ-4279, a first-in-class USP1 small-molecule inhibitor for DNA damage response, was out-licensed to Roche. The CRISPRomics platform enables genome-scale, in vivo validated target discovery, while the ExPRESS process enables efficient manufacturing of edited cell therapies from both surgical resections and core biopsies.

Differentiator

Problem solved

Functional benefit

Products and services

  • CRISPRomics® Platform Proprietary genome-scale functional genomics platform using CRISPR/Cas9 technology to systematically identify and validate therapeutic targets across cancer and immune cells. Screens over 20,000 genes across more than 600 cancer lines and immune cell types (T cells, NK cells, T regulatory cells) for unbiased, in vivo validated target discovery.
  • ExPRESS™ Manufacturing Process Proprietary next-generation manufacturing process (Ex Vivo, Potent, Economical, Streamlined, Simple) for producing single and multiplex CRISPR/Cas9-edited eTIL therapies. Generates a cryopreserved product with maximized cancer-killing potential from surgical resections and core biopsies using a 22-day manufacturing cycle across 10+ solid tumor types.
  • KSQ-001EX Investigational CRISPR/Cas9-engineered Tumor Infiltrating Lymphocyte (eTIL®) therapy in which the SOCS1 gene is inactivated, manufactured using the ExPRESS™ process. In Phase 1/2 clinical study for advanced solid tumors including melanoma, head and neck squamous cell carcinoma, and non-small cell lung cancer.
  • KSQ-004EX Dual-edit eTIL investigational therapy in which both the Regnase-1 and SOCS1 genes are inactivated by CRISPR/Cas9 gene editing, manufactured using the ExPRESS™ process. In Phase 1/2 clinical study for advanced solid tumors including melanoma, head and neck squamous cell carcinoma, non-small cell lung cancer, colorectal cancer, pancreatic cancer, and cervical cancer.
  • KSQ-4279 (RO7623066/RG6614) First-in-class, potent, and selective small-molecule inhibitor of USP1 (Ubiquitin-specific processing protease 1), a protein regulating DNA damage response (DDR). Licensed worldwide to Roche for development and commercialization; previously studied in Phase 1 clinical trial in patients with advanced solid tumors including BRCA-mutant and HRD cancers.

Quantifiable outcome

  • 10-fold increase in anti-tumor activity in vivo with CT-1 edited T cells
  • +2 more outcomes

Companies that use KSQ Therapeutics

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

KSQ Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

KSQ Therapeutics partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered key and core.

  • The University of Texas MD Anderson Cancer CenterkeyStrategic or Co-development Partner · 24 September 2024Clinical collaboration for KSQ-004EX Phase 1/2 study. MD Anderson provides clinical trial site and principal investigator Dr. Rodabe Amaria (professor of Melanoma Medical Oncology). Also collaborates on KSQ-001EX study.
  • CTMC (Cell Therapy Manufacturing Center)coreStrategic or Co-development Partner · 6 September 2023Strategic collaboration with CTMC, a joint venture between National Resilience, Inc. and MD Anderson Cancer Center. CTMC provides full process development and manufacturing support for KSQ's lead eTIL programs KSQ-001EX and KSQ-004EX, advancing toward clinical studies for solid tumors. Manufacturing uses KSQ's ExPRESS process.
  • RochecoreOEM/ Whitelabel/ Licensing Partner · 13 July 2023Worldwide license and collaboration agreement for KSQ-4279, a first-in-class USP1 inhibitor for cancer. Roche assumes development responsibilities including full clinical development from 2024. KSQ receives upfront payment and eligible for milestone and royalty payments. KSQ-4279 is in Phase 1 clinical trial for advanced solid tumors.
  • Takeda Pharmaceutical Company (Expansion)coreStrategic or Co-development Partner · 17 May 2023Expanded collaboration focused on novel tumor-intrinsic target discovery and validation. Takeda provides upfront payment and investment in double-digit millions. KSQ eligible for up to $510M in future payments if all milestones achieved, plus royalties on net sales. Expansion adds work on tumor-intrinsic targets to ongoing NK and T-cell collaboration.
  • Ono Pharmaceutical Co., Ltd.keyOEM/ Whitelabel/ Licensing Partner · 25 January 2023Ono Pharmaceutical acquired multiple research-stage DNA damage response (DDR) programs identified using KSQ's CRISPRomics platform. All programs are novel with potential for first-in-class therapies. ONO provided double-digit million upfront payment with near-term milestones expected and potential long-term value into triple-digit millions plus royalties on net sales.
  • Takeda Pharmaceutical CompanycoreStrategic or Co-development Partner · 13 January 2021Broad strategic collaboration to research, develop and commercialize novel immune-based therapies for cancer. KSQ granted Takeda exclusive worldwide royalty-bearing license for cell and non-cell therapy products modulating targets identified using CRISPRomics. Deal includes two T-cell programs and NK cell target discovery. Potential for $100M+ upfront and preclinical milestones, up to $400M+ per program additional milestones plus royalties. KSQ retains U.S. cost/profit-sharing option on one product.
  • MaxCytekeyTechnology or Integration · 4 December 2019Development and commercialization agreement using MaxCyte's Flow Electroporation technology and ExPERT instruments for KSQ's eTIL programs. KSQ obtains non-exclusive clinical and commercial use rights to MaxCyte's cell engineering platform for multiple adoptive cell therapies. MaxCyte eligible for milestone payments and licensing fees.
  • CRISPR TherapeuticskeyTechnology or Integration · 15 October 2019License agreement for mutual IP access. CRISPR Therapeutics gains non-exclusive access to KSQ IP for editing certain novel gene targets in its allogeneic oncology cell therapy programs. KSQ gains non-exclusive access to CRISPR Therapeutics IP for editing novel gene targets in its autologous eTIL cell programs.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

KSQ Therapeutics competitors and assessment

Company assessment

Direct peers

  • Beam Therapeutics: Beam is a clinical-stage precision genetic medicines company using base editing, a CRISPR-derived technology. Comparable platform-driven biotech with similar oncology focus and partnership approach (Pfizer, Verve).
  • Intellia Therapeutics: Intellia is a clinical-stage CRISPR/Cas9 platform company developing both ex vivo (cell therapy) and in vivo gene editing programs. Similar platform-technology profile and partnership-driven business model with comparable Big Pharma validation (Novartis, Regeneron).
  • Iovance Biotherapeutics: Iovance is the most direct peer - the leader in TIL therapy with FDA-approved lifileucel for melanoma. KSQ's eTIL programs compete head-to-head in melanoma and other solid tumors, and Iovance's commercial experience directly benchmarks KSQ's opportunity and challenges.
  • Adaptimmune: Adaptimmune develops engineered T-cell receptor (TCR) therapies for solid tumors, with approved Tecelra for synovial sarcoma. Direct competitor in the solid tumor cell therapy space where KSQ's eTIL programs also operate.
  • Editas Medicine: Editas is a clinical-stage CRISPR gene editing company developing edited cell therapies for oncology and genetic diseases. Comparable platform-technology approach and similar partnership-driven development model.
  • CRISPR Therapeutics: CRISPR Therapeutics is the most direct CRISPR platform peer, with its Cas9-based allogeneic CAR-T programs. KSQ has a mutual license with CRISPR Therapeutics (2019) and competes for the same gene-edited cell therapy opportunity, with overlapping target space.

Emerging players

  • Cellectis: Cellectis develops TALEN-based gene-edited allogeneic CAR-T cell therapies. Comparable gene-edited cell therapy approach but earlier stage in clinical development and focused on allogeneic platform.
  • Allogene Therapeutics: Allogene is a clinical-stage allogeneic CAR-T company with multiple programs in lymphoma and other hematologic malignancies. Comparable cell therapy platform approach and Big Pharma backing (Pfizer, Cellectis founder).
  • Caribou Biosciences: Caribou is a clinical-stage CRISPR genome-edited allogeneic CAR-T and NK cell therapy company. Comparable gene-edited cell therapy technology profile but with allogeneic (off-the-shelf) rather than KSQ's autologous approach.
  • Fate Therapeutics: Fate develops iPSC-derived off-the-shelf NK and T-cell cancer immunotherapies. Comparable cell therapy modality for oncology with multiple Big Pharma partnerships (J&J, Ono), analogous to KSQ's licensing model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

KSQ Therapeutics social profiles

Digital presence

KSQ Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

KSQ Therapeutics leadership team

Management profile

Number of profiles

Profiles11 records

KSQ Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

KSQ Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KSQ Therapeutics

What does KSQ Therapeutics do?

KSQ Therapeutics is a clinical-stage biotechnology company that discovers and develops oncology therapeutics using its proprietary CRISPRomics® genome-scale functional genomics platform. The company is advancing a pipeline of CRISPR/Cas9-engineered Tumor Infiltrating Lymphocyte (eTIL®) therapies, including KSQ-001EX and KSQ-004EX, manufactured via its proprietary ExPRESS™ process, and has out-licensed the small-molecule USP1 inhibitor KSQ-4279 to Roche.

Is KSQ Therapeutics a public or private company?

KSQ Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was KSQ Therapeutics founded?

KSQ Therapeutics was founded in 2015. It employs 51 to 100 people.

Where is KSQ Therapeutics based?

KSQ Therapeutics is headquartered in Lexington, United States, in the North America region.

How does KSQ Therapeutics make money?

Three revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are equity Financing and program Acquisitions.

Who are KSQ Therapeutics's main competitors?

Direct peers on record are Beam Therapeutics, Intellia Therapeutics, Iovance Biotherapeutics, Adaptimmune, Editas Medicine and CRISPR Therapeutics. Emerging players are Cellectis, Allogene Therapeutics, Caribou Biosciences and Fate Therapeutics.

Does KSQ Therapeutics have an API?

No public API is recorded for KSQ Therapeutics.

What industry is KSQ Therapeutics in?

KSQ Therapeutics's product category is Oncology Biotechnology / Cell Therapy. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAAIAG, CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Targeted OncologyFirst Patient Receives KSQ-004EX for Advanced CancerThe first patient has been dosed with KSQ-004EX, a novel CRISPR-engineered tumor infiltrating lymphocyte therapy, during a phase 1/2 trial aimed at treating advanced solid tumors. This investigational therapy, developed by KSQ Therapeutics, shows promise due to its dual gene inactivation strategy which enhances anti-tumor functionality. The trial evaluates its safety and tolerability, with a primary endpoint focusing on antitumor activity across various advanced cancer indications.The Pharma LetterDeal-hungry Ono acquires KSQ programs in oncologyKSQ Therapeutics has announced a deal in which Ono Pharmaceutical has acquired several research-stage DNA damage response programs developed using KSQ’s CRISPRomics platform. This acquisition highlights Ono's focus on expanding its oncology portfolio through innovative therapies.Labiotech.euTIL therapies: A milestone in cancer treatmentThe FDA approved Iovance Biotherapeutics' TIL therapy Amtagvi for advanced melanoma in 2024, the first non-CAR-T cell therapy for solid tumors. The one-time treatment costs $515,000 per patient, and other companies are developing engineered TILs to reduce toxicity and expand indications.FierceBiotechHow a CMO Approaches Clinical Development of a CRISPR-Engineered TIL TherapyKSQ Therapeutics is conducting two Phase I/II trials on their CRISPR-engineered TIL products, KSQ-001EX and KSQ-004EX. The trials aim to enhance the efficacy of Tumor Infiltrating Lymphocytes (TIL) by targeting SOCS1 and Regnase-1 genes for better tumor response in solid tumors. Success in these trials could allow these gene edits to be adapted for use in multiple T cell therapies in the future.PR NewswireTumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsightDelveInsight has released a comprehensive market report projecting significant growth in the tumor-infiltrating lymphocyte (TIL) therapies market across the 7MM (United States, EU-4, UK, and Japan), with the market expected to surge substantially by 2034. The report highlights key developments including Iovance Biotherapeutics' AMTAGVI receiving FDA approval in 2024 for advanced melanoma, marking the first regulatory validation of a TIL therapy, alongside ongoing clinical progress from Obsidian Therapeutics (OBX-115) and KSQ Therapeutics (KSQ-004EX). Several companies including Obsidian Therapeutics, Biosyngen, KSQ Therapeutics, and Iovance Biotherapeutics are developing novel TIL therapies targeting various solid tumors, with the competitive landscape becoming increasingly dynamic through strategic partnerships and gene editing technologies.CRISPR MedicineNews: The Latest Updates From the Gene-Editing Clinical Trials (October 2024)Intellia Therapeutics initiated a pivotal Phase 3 trial for its gene-editing therapy NTLA-2002 to treat hereditary angioedema, while Poseida Therapeutics reported positive interim data for its CAR-T candidate P-BCMA-ALLO1 in multiple myeloma. Additionally, YolTech Therapeutics received Orphan Drug Designation from the FDA for YOLT-203, and KSQ Therapeutics obtained FDA clearance to begin clinical trials for its CRISPR-edited TIL therapy KSQ-004EX.InsideprecisionmedicineGoldenEye: KSQ Doses First Solid Tumor Patient with CRISPR/Cas9 eTILsKSQ Therapeutics has dosed the first patient in its Phase I/II clinical trial for KSQ-001EX, a CRISPR/Cas9-engineered tumor-infiltrating lymphocyte therapy targeting solid tumors. This milestone marks the progression of the company's lead candidate into human trials after previously licensing its small molecule inhibitor KSQ-4279 to Roche.MdandersonASCO: Novel targeted cancer therapies demonstrate activity and safety in metastatic solid tumorsResearchers from MD Anderson Cancer Center presented preliminary data at the 2024 ASCO Annual Meeting on two novel cancer therapies: the antibody-drug conjugate M9140 and the USP1 inhibitor RO7623066. The studies, supported by EMD Serono and Roche/KSQ Therapeutics respectively, demonstrated manageable safety profiles and early signs of anti-tumor activity in patients with advanced solid tumors. Both therapies are currently undergoing further evaluation to determine optimal dosing and long-term effectiveness.Business Wire BlogKSQ Therapeutics Enters Worldwide License Agreement with Roche for KSQ-4279, a Clinical-Stage USP1 Inhibitor for CancerKSQ Therapeutics entered a worldwide license and collaboration agreement with Roche for the development and commercialization of KSQ-4279, a clinical-stage USP1 inhibitor for cancer. Under the terms of the deal, Roche assumes full development responsibilities while KSQ receives an upfront payment and is eligible for milestone and royalty payments. This partnership allows KSQ to focus on its own immunotherapy programs while leveraging Roche's resources to advance the novel drug candidate.BioSpaceKSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ’s CRISPRomics® Platform TechnologyOno Pharmaceutical Co., Ltd. has acquired multiple research-stage oncology programs from KSQ Therapeutics that were identified using KSQ’s CRISPRomics platform technology. The transaction includes double-digit million upfront payments, potential near-term milestones, and long-term royalties based on net sales. This agreement allows KSQ to focus on its other programs while enabling Ono to advance these novel targets toward clinical studies.